Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice

Cancer Immunology, Immunotherapy

Volumn 54, Issue 6, 2005, Pages 535-5475

  Melder, Robert J ^b   Osborn, Blaire L ^a   Riccobene, Todd ^c   Kanakaraj, Palanisamy ^a   Wei, Ping ^d   Chen, Guoxian ^a   Stolow, David ^e   Halpern, Wendy Green ^a   Migone, Thi Sau ^a   Wang, Qi ^a   Grzegorzewski, Krzysztof J ^a   Gallant, Gilles ^a  

^a GLAXOSMITHKLINE   (United States)

^b MEDTRONIC INC   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d AMGEN INC   (United States)

^e MO BIO Laboratories Inc   (United States)

Author keywords

Albuleukin; Albumin; Fusion protein; Interleukin 2; Pharmacokinetics; Tumor growth

Indexed keywords

ALBULEUKIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR; RECOMBINANT HUMAN SERUM ALBUMIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; FEMALE; HALF-LIFE; HUMANS; INTERLEUKIN-2; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN;

EID: 20944431599     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0624-7     Document Type: Article

References (38)

1. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Brocker EB (2002) Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 87:840
2. Bent-Hansen L (1991a) Initial plasma disappearance and tissue uptake of 131I-albumin in normal rabbits. Microvasc Res 41:345
3. Bent-Hansen L (1991b) Whole body capillary exchange of albumin. Acta Physiol Scand Suppl 603:5
4. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189
5. Chang AE, Hyatt CL, Rosenberg SA (1984) Systemic administration of recombinant human interleukin-2 in mice. J Biol Response Mod 3:561
6. Eisenthal A, Cameron RB, Rosenberg SA (1990) Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 144:4463
7. Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA (1987) Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47:2771
8. Gaffen SL, Goldsmith MA, Greene WC (1998) Interleukin-2 and the interleukin-2 receptor. The cytokine handbook. Academic, San Diego
9. Hanes J, Sills A, Zhao Z, Suh KW, Tyler B, DiMeco F, Brat DJ, Choti MA, Leong KW, Pardoll DM, Brem H (2001) Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18:899
10. Kim TS, Xu WS, Sun T, Cohen EP (1995) Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res 5:217
11. Koppenhagen FJ, Kupcu Z, Wallner G, Crommelin DJ, Wagner E, Storm G, Kircheis R (1998) Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. Clin Cancer Res 4:1881
12. Krup OC, Kroll I, Bose G, Falkenberg FW (1999) Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 22:525
13. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY (2001) Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 61:3281
14. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865
15. Milici AJ, Watrous NE, Stukenbrok H, Palade GE (1987) Transcytosis of albumin in capillary endothelium. J Cell Biol 105:2603
16. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260
17. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal bone marrows. Science 193:1007
18. Neville ME, Robb RJ, Popescu MC (2001) In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. Cytokine 16:239
19. Parker JC, Ryan J, Taylor AE (1984) Plasma-lymph albumin kinetics, total lymph flow, and tissue hematocrit in normally hydrated dog lungs. Microvasc Res 28:254
20. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G (1987) Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 6:171
21. Peters T Jr (1996) All about albumin; biochemistry, genetics, and medical applications. Academic, San Diego
22. Piscitelli SC, Bhat N, Pau A (2000) A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection. Drug Safety 22:19
23. Robb RJ, Smith KA (1981) Heterogeneity of human T cell growth factor(s) due to variable glycosylation. Mol Immunol 18:1087
24. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380
25. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT (1989) Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49:7086
26. Rutili G, Arfors KE (1977) Protein concentration in interstitial and lymphatic fluids from the subcutaneous tissue. Acta Physiol Scand 99:1
27. Salup RR, Herberman RB, Chirigos MA, Back T, Wiltrout RH (1985) Therapy of peritoneal murine cancer with biological response modifiers. J Immunopharmacol 7:417
28. Sato T (2002) Locoregional immuno(bio)therapy for liver metastases. Semin Oncol 29:160
29. Schnitzer JE, Oh P (1994) Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem 269:6072
30. Schultze HE, Heremans JF (1966) Molecular biology of human proteins, with special reference to plasma proteins. Elsevier, Amsterdam
31. Smith KA (2000) IL-2. In: Oppenheim JJ, Feldman M (eds) Cytokine reference: a compendium of cytokines and other mediators of host defense. Academic, New York
32. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302:305
33. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38
34. Woll E, Bedikian A, Legha SS (1999) Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 9:575
35. Yao Z, Dai W, Perry J, Brechbiel MW, Sung C (2004) Effect of albumin fusion on the biodistribution of inter-leukin-2. Cancer Immunol Immunother 53:404
36. Yeh P, Landais D, Lemaitre M, Maury I, Crenne JY, Becquart J, Murry-Brelier A, Boucher F, Montay G, Fleer R et al. (1992) Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA 89:1904
37. Yuan F (1998) Transvascular drug delivery in solid tumors. Semin Radiat Oncol 8:164
38. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752